PDGFRB and neoplasm: Overcoming resistance to osimertinib remains a key objective, and targeting the tumor vasculature in the tumor microenvironment (TME) with anti-angiogenic agents (e.g., anlotinib, a multi-target TKI that targets VEGFR, FGFR, PDGFR, and c-kit) offers a potential solution [275].